Alveron Pharma has successfully completed its first-in-human trial of OKL-1111, a new drug for the rapid treatment of intracranial haemorrhage associated with the use of anticoagulants or platelet inhibitors. The study was conducted at Hammersmith Medicines Research in London. OKL-1111 was well-tolerated in the trial with healthy human volunteers and showed no more adverse events above those in the placebo groups. Volunteers also received an anticoagulant and a pharmacodynamic effect was observed with OKL-1111 administration.
News
Press release
Macomics Expands in Edinburgh with Move to Roslin Innovation Centre and Announces Appointment of Professor Paul Crocker to SAB
Edinburgh and Cambridge, UK, 29 September 2023 - Macomics Ltd, a leader in macrophage drug discovery, continues its growth trajectory with expansion in Edinburgh into dedicated facilities within the Roslin Innovation Centre. The company has also announced the appointment of Professor Paul Crocker FRSE, Emeritus Professor of Glycoimmunology, University of Dundee to its Scientific Advisory Board (SAB).
Cambridge, UK – 27 September 2023 – Eagle Genomics (“Eagle”) is pleased to announce it has raised additional financing of £3 million (USD $4 million) with continued participation from existing investors Environmental Technologies Fund, abrdn plc, and a consortium of investors headed by Granpool Innovative Investments, to further deploy its pioneering software platform that enables corporate customers to explore and monetize on microbiome-related research. The current funding brings Eagle’s total capital raising to over £20 million (USD $25 million) over the last 12 months.
Reflects evolution of the Company from research and development towards scale-up and commercialization
We are delighted to announce that our latest whitepaper, in collaboration with Back Bay Life Science Advisors: 'Microbiome Medicinal Products: Concept to Commercial', is now available to read and download.
Press release
Macomics Launches Super Triathlon Challenge to Raise Funds for Prof. Jeffrey Pollard Memorial Fund
Edinburgh and Cambridge, UK, 25 October 2023 – Macomics Ltd, a leader in macrophage drug discovery, is delighted to announce that it has launched the Macomics Hyper-Triathlon Challenge, in honour of its co-founder Prof. Jeffrey Pollard, who passed away earlier this year, to raise funds for the newly established Jeff Pollard’s memorial fund.
Sygnature Discovery and UBE Corporation have begun a collaboration on a Hit-to-Lead program to identify SHP2 degraders.
SHP2 is a tyrosine-specific phosphatase implicated in human cancers and the objective is to develop potent bifunctional compounds with excellent ADME and PK properties for efficient degradation of SHP2.
Through the collaboration, the teams have discovered unique hit compounds (profile: single-digit nM DC50 and approximately 100% Dmax) utilizing Sygnature Discovery’s innovative proprietary CHARMED technology platform.
Medicilon once again won the "Top 50 Chinese Pharmaceutical R&D" in 2022-2023 based on its comprehensive strength.
Cambridge, UK: Following the resounding success of the inaugural edition of the tech Kickstarter Competition in Jan 2023, o2h technology (a business vertical of the o2h group) is excite to launch the second edition of the o2h tech kickstarter competition designed to support seed stage life science, greentech, and tech/AI companies with their MVP, web, mobile app design & development needs.
Following the resounding success of its inaugural edition in Jan 2023, o2h technology (a business vertical of the o2h group) is excited to launch the second edition of the o2h tech kickstarter competition designed to support seed stage life science, greentech, and tech/AI companies with their MVP, web, mobile app design & development needs.